Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Scientific Officer | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,477 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-22 · Grant · Acquired 7,866 · Balance 31,149 F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Row 2 · 2026-01-22 · Grant · Acquired 3,328 · Balance 34,477 F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2018 Filed Jul 3, 2018 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 31,796 | $165.46 | $5,260,966.16 |
DisclosureSEC source: 0001209191-18-041091 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,113 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $165.46 (range $165.13 to $166.05). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,535 | $161.57 | $1,217,429.95 |
DisclosureSEC source: 0001209191-18-041091 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,909 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,649 | $86.52 | $1,007,871.48 |
DisclosureSEC source: 0001209191-18-041091 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-18-041091 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 98 | $155.78 | $15,266.44 |
DisclosureSEC source: 0001209191-18-030546 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,999 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $153.84 | $15,384.00 |
DisclosureSEC source: 0001209191-18-010068 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,999 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $153.11 | $107,177.00 |
DisclosureSEC source: 0001209191-18-010068 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,099 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $153.11 (range $152.71 to $153.59). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,953 | $151.40 | $295,684.20 |
DisclosureSEC source: 0001209191-18-010068 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,799 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $151.40 (range $151.02 to $151.90). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $150.67 | $286,273.00 |
DisclosureSEC source: 0001209191-18-010068 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,752 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $150.67 (range $150.01 to $150.97). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,750 | $149.23 | $261,152.50 |
DisclosureSEC source: 0001209191-18-010068 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,652 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.23 (range $148.77 to $149.74). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 19,566 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008519 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,566 Underlying: Common Stock · 19,566 shares Expires 2028-02-05 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008519 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,402 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008519 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,965 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/03/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · derivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $169.49 | $16,949.00 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,761 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $167.81 | $16,781.00 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,861 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 996 | $166.12 | $165,455.52 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,961 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $166.12 (range $165.81 to $166.43). Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $165.24 | $99,144.00 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,957 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $165.24 (range $164.80 to $165.71). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 22:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-18-007618 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-005201 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,164 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,796 | $160.00 | $287,360.00 |
DisclosureSEC source: 0001209191-18-005201 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,761 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-18-005201 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,955 | $159.41 | $630,466.55 |
DisclosureSEC source: 0001209191-18-003986 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,761 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $159.41 (range $159.21 to $159.65). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,585 | $158.82 | $1,681,109.70 |
DisclosureSEC source: 0001209191-18-003986 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,716 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $158.82 (range $158.21 to $159.20). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,130 | $157.71 | $966,762.30 |
DisclosureSEC source: 0001209191-18-003986 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,301 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $157.71 (range $157.20 to $158.19). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,767 | $156.63 | $1,843,065.21 |
DisclosureSEC source: 0001209191-18-003986 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,431 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $156.63 (range $156.19 to $157.18). Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 23,813 | $155.77 | $3,709,351.01 |
DisclosureSEC source: 0001209191-18-003986 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,198 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $155.77 (range $155.19 to $156.17). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 206 | $149.80 | $30,858.80 |
DisclosureSEC source: 0001209191-17-061528 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.80 (range $149.28 to $150.25). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $147.71 | $14,771.00 |
DisclosureSEC source: 0001209191-17-061528 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,217 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-17-051354 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,960 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,796 | $160.00 | $287,360.00 |
DisclosureSEC source: 0001209191-17-051354 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-17-051354 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-17-046025 · doc4.xml · derivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,979 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-17-046025 · doc4.xml · derivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,756 Underlying: Common Stock · 8,979 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 28,979 | $161.00 | $4,665,619.00 |
DisclosureSEC source: 0001209191-17-046025 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $81.54 | $1,630,800.00 |
DisclosureSEC source: 0001209191-17-046025 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 8,979 | $91.05 | $817,537.95 |
DisclosureSEC source: 0001209191-17-046025 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-17-037928 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $130.00 | $975,000.00 |
DisclosureSEC source: 0001209191-17-037928 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 05, 2017 Filed Jun 5, 2017 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $72.14 | $541,050.00 |
DisclosureSEC source: 0001209191-17-037928 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 181 | $114.37 | $20,700.97 |
DisclosureSEC source: 0001209191-17-033077 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $63.14 | $0.00 |
DisclosureSEC source: 0001209191-17-029274 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $120.00 | $900,000.00 |
DisclosureSEC source: 0001209191-17-029274 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $63.14 | $473,550.00 |
DisclosureSEC source: 0001209191-17-029274 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,403 | $87.68 | $561,415.04 |
DisclosureSEC source: 0001209191-17-011119 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,011 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $87.68 (range $87.29 to $88.23). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 37,278 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-008397 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,278 Underlying: Common Stock · 37,278 shares Expires 2027-02-02 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008397 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,414 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,794 | $0.01 | $47.94 |
DisclosureSEC source: 0001209191-17-008397 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,210 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/02/2016 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2017. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 28,735 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-16-095839 · doc4.xml · derivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,735 Underlying: Common Stock · 28,735 shares Expires 2026-02-01 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,416 | $0.01 | $144.16 |
DisclosureSEC source: 0001209191-16-095839 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,416 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.